Catalent (NYSE:CTLT) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Catalent (NYSE:CTLTFree Report) in a report released on Friday morning. The firm issued a sell rating on the stock.

CTLT has been the topic of several other research reports. Royal Bank of Canada reiterated a sector perform rating and set a $63.50 price objective on shares of Catalent in a research report on Tuesday, February 20th. Stephens restated an equal weight rating and issued a $63.50 price target on shares of Catalent in a research report on Thursday, April 4th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of Hold and an average target price of $54.05.

Read Our Latest Analysis on Catalent

Catalent Stock Down 0.5 %

CTLT stock opened at $55.21 on Friday. The company has a debt-to-equity ratio of 1.37, a current ratio of 2.51 and a quick ratio of 1.77. The stock has a market capitalization of $9.99 billion, a price-to-earnings ratio of -9.05, a PEG ratio of 6.67 and a beta of 1.20. The business’s fifty day moving average price is $55.63 and its two-hundred day moving average price is $52.86. Catalent has a fifty-two week low of $31.80 and a fifty-two week high of $60.20.

Catalent (NYSE:CTLTGet Free Report) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of $0.21 by ($0.36). The firm had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.11 billion. Catalent had a negative return on equity of 2.73% and a negative net margin of 26.61%. On average, equities analysts anticipate that Catalent will post 0.28 earnings per share for the current year.

Insider Activity at Catalent

In other news, insider Ricky Hopson sold 1,401 shares of Catalent stock in a transaction dated Tuesday, June 4th. The stock was sold at an average price of $54.26, for a total transaction of $76,018.26. Following the sale, the insider now directly owns 20,617 shares of the company’s stock, valued at $1,118,678.42. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.31% of the stock is currently owned by insiders.

Institutional Trading of Catalent

A number of hedge funds have recently made changes to their positions in CTLT. Nomura Holdings Inc. boosted its stake in shares of Catalent by 149.4% during the fourth quarter. Nomura Holdings Inc. now owns 11,487,342 shares of the company’s stock valued at $516,126,000 after purchasing an additional 6,881,914 shares in the last quarter. Norges Bank bought a new position in shares of Catalent during the fourth quarter worth about $116,021,000. Cadian Capital Management LP raised its position in shares of Catalent by 91.0% during the third quarter. Cadian Capital Management LP now owns 5,304,784 shares of the company’s stock worth $241,527,000 after acquiring an additional 2,526,750 shares during the last quarter. Ameriprise Financial Inc. raised its position in shares of Catalent by 65.9% during the third quarter. Ameriprise Financial Inc. now owns 3,483,494 shares of the company’s stock worth $158,601,000 after acquiring an additional 1,384,313 shares during the last quarter. Finally, Capital World Investors raised its position in shares of Catalent by 6.1% during the fourth quarter. Capital World Investors now owns 19,079,994 shares of the company’s stock worth $857,264,000 after acquiring an additional 1,098,474 shares during the last quarter.

About Catalent

(Get Free Report)

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.

Featured Stories

Analyst Recommendations for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.